Quince Therapeutics (QNCX) Other Non-Current Assets (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Other Non-Current Assets of $78000.0 for Q1 2026, down 99.22% year-over-year from $10.0 million in Q1 2025, and down 95.57% quarter-over-quarter from $1.8 million in Q4 2025.
Quince Therapeutics (QNCX) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Quince Therapeutics' Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $78000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 99.22% year-over-year to $78000.0; the TTM figure through Mar 2026 stood at $78000.0 (down 99.22% YoY), while the FY2025 annual figure was $1.8 million, down 81.64% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $78000.0, down from $1.8 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $11.9 million in Q3 2025, with the low at $17000.0 in Q3 2022.
- The 5-year median for Other Non-Current Assets is $8.5 million (2023), against an average of $6.1 million.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets increased 27.52% in 2025, then plunged 99.22% in 2026.
- Quince Therapeutics' Other Non-Current Assets stood at $17000.0 in 2022, then surged by 50158.82% to $8.5 million in 2023, then climbed by 12.17% to $9.6 million in 2024, then slumped by 81.64% to $1.8 million in 2025, then sank by 95.57% to $78000.0 in 2026.
- Business Quant data shows QNCX's Other Non-Current Assets at $78000.0 in Q1 2026, $1.8 million in Q4 2025, and $11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78,000.00 |
| Dec 31, 2025 | 1.76 Mn |
| Sep 30, 2025 | 11.87 Mn |
| Jun 30, 2025 | 11.22 Mn |
| Mar 31, 2025 | 9.95 Mn |
| Dec 31, 2024 | 9.58 Mn |
| Sep 30, 2024 | 9.51 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Mar 31, 2024 | 8.47 Mn |
| Dec 31, 2023 | 8.54 Mn |
| Sep 30, 2022 | 17,000.00 |
| Jun 30, 2022 | 47,000.00 |
| Mar 31, 2022 | 29,000.00 |
| Dec 31, 2021 | 194,000.00 |
| Sep 30, 2021 | 193,000.00 |
| Jun 30, 2021 | 145,000.00 |
| Mar 31, 2021 | 39,000.00 |
| Dec 31, 2020 | 39,000.00 |
| Sep 30, 2020 | 209,000.00 |
| Jun 30, 2020 | 244,000.00 |